Every

discovery deserves
a clearer path to patients.

Regulatory strategy,

clinical technology,

and

market access

under one roof,

built for approvals and outcomes rather than slide decks.

  • FDA

  • EMA

  • MHRA

  • PMDA

  • Swissmedic

  • Health Canada

  • TGA

  • ANVISA

Every engagement begins with one honest question.

No pitch decks, no junior hand-offs. Before we propose anything, a partner sits with your team, finds the decision that matters most — and builds the evidence around it.

Scientific consultants discussing evidence in a bright clinical research office

Where is our evidence weakest?

Your Phase II endpoints won’t satisfy European HTA bodies. That’s a launch problem, not a trial problem.

Can we fix it without delaying the readout?

Yes. Add one validated secondary endpoint and pre-register the analysis. Let’s start there.

  • Hypotheses become protocols

  • Protocols become evidence

  • Evidence becomes approval

  • Approval becomes access

  • Access becomes outcomes

White medical research atrium

– In medicine, clarity is not a style. It is a safety standard.

Where science, regulation and markets finally meet.

Sterile manufacturing in the White Architecture photographic series

Scientific depth

Partners with MD, PhD and PharmD backgrounds who read the data themselves — not through a slide deck.

Regulatory fluency

Former agency reviewers and notified-body assessors who know how decisions are actually made.

Technology & AI

Data scientists and engineers who validate algorithms, models and digital endpoints to clinical standard.

Turning insight into structured execution.

Precision microscopy in the White Architecture photographic series

01

Diagnose

We interrogate the data, the plan and the people to find the one decision that changes the outcome.

Clinical protocol planning in the White Architecture photographic series

02

Design

Options are modelled against evidence, cost and time — then stress-tested with expert panels.

Research evidence review in the White Architecture photographic series

03

Deliver

Partners stay hands-on through submissions, agency meetings and board reviews.

Remote patient monitoring in the White Architecture photographic series

04

Sustain

Clear milestones, monthly read-outs and a team that remains on call as the science evolves.

140+

Agency interactions prepared

$9bn

Transactions advised on

94%

Programmes delivered on time

300+

Specialists in our expert network

Clear pharmaceutical glass vials

– We remove everything that is not evidence. What remains is the decision.

Why not simply hire a larger firm?

Typical approach

Generalist teams rotated across industries

Slide-heavy reports, weeks after the decision

Junior analysts do most of the work

Advice independent of regulators’ reality

Hourly billing with open-ended scope

Illuminate

Clinicians, scientists and ex-regulators only

Decision memos timed to your governance calendar

Partners stay hands-on from first call to filing

Mock panels with former agency reviewers

Fixed fees against defined deliverables

What leadership teams tell us afterwards.

  • The rare advisor who is equally comfortable in front of an agency panel and inside a data room. Every recommendation came with the evidence behind it.

    Client portrait

    Dr. Lena Brandt

  • They spoke fluent machine learning and fluent FDA. Our clearance came months earlier than our own plan assumed.

    Client portrait

    Tomas Riedel

  • Calm, precise and unusually honest. They told us what we needed to hear, not what we wanted to hear — and that saved the programme.

    Client portrait

    Priya Raman

  • For the first time our digital programme was evaluated with the same rigour as a new drug. The board noticed.

    Client portrait

    Dr. Ana Kovač

  • Their investment memo was the one document our committee actually read cover to cover.

    Client portrait

    Olivia Hart

Questions? We’re glad you asked.

Dr. Helena Voss

Dr. Helena Voss

Still deciding? A 20-minute call with a partner usually settles it.